The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus
出版年份 2013 全文链接
标题
The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus
作者
关键词
-
出版物
PLoS One
Volume 8, Issue 3, Pages e60394
出版商
Public Library of Science (PLoS)
发表日期
2013-03-29
DOI
10.1371/journal.pone.0060394
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Peptide That Ameliorates Lupus Up-Regulates the Diminished Expression of Early Growth Response Factors 2 and 3
- (2014) U. Sela et al. JOURNAL OF IMMUNOLOGY
- The Suppression of Murine Lupus by a Tolerogenic Peptide Involves Foxp3-Expressing CD8 Cells That Are Required for the Optimal Induction and Function of Foxp3-Expressing CD4 Cells
- (2014) A. Sharabi et al. JOURNAL OF IMMUNOLOGY
- Systemic Lupus Erythematosus
- (2011) George C. Tsokos NEW ENGLAND JOURNAL OF MEDICINE
- A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus
- (2010) Edna Mozes et al. AUTOIMMUNITY REVIEWS
- Type I interferon (IFN-α/β) rescues B-lymphocytes from apoptosis via PI3Kδ/Akt, Rho-A, NFκB and Bcl-2/BclXL
- (2010) Gamal Badr et al. CELLULAR IMMUNOLOGY
- A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide
- (2010) Smadar Lapter et al. IMMUNOLOGY
- A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-γ signaling in lupus-affected (NZB×NZW)F1 mice
- (2009) Amir Sharabi et al. CLINICAL IMMUNOLOGY
- B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus
- (2009) Reshmi Parameswaran et al. CLINICAL IMMUNOLOGY
- The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients
- (2009) Zev M. Sthoeger et al. HUMAN IMMUNOLOGY
- A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis
- (2009) Hava Ben-David et al. IMMUNOLOGY
- Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expression
- (2009) Zev M. Sthoeger et al. JOURNAL OF AUTOIMMUNITY
- Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide
- (2009) Amir Sharabi et al. JOURNAL OF AUTOIMMUNITY
- Interferon-alpha (IFN-α)–conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients
- (2009) Margherita Gigante et al. JOURNAL OF IMMUNOTHERAPY
- In Vivo Dynamical Interactions between CD4 Tregs, CD8 Tregs and CD4+CD25− Cells in Mice
- (2009) Arnon Arazi et al. PLoS One
- IFN kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model
- (2009) D. Zagury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α–producing antigen-presenting cells
- (2008) Bing Yan et al. ARTHRITIS AND RHEUMATISM
- Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells
- (2008) A. Farkas et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models
- (2008) Uri Sela et al. IMMUNOLOGY
- BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000
- (2007) C-S Yee et al. ANNALS OF THE RHEUMATIC DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started